Skip to main content
Erschienen in: Strahlentherapie und Onkologie 9/2021

14.07.2021 | Review Article

Value of PET imaging for radiation therapy

verfasst von: Constantin Lapa, Ursula Nestle, Nathalie L. Albert, Christian Baues, Ambros Beer, Andreas Buck, Volker Budach, Rebecca Bütof, Stephanie E. Combs, Thorsten Derlin, Matthias Eiber, Wolfgang P. Fendler, Christian Furth, Cihan Gani, Eleni Gkika, Anca-L. Grosu, Christoph Henkenberens, Harun Ilhan, Steffen Löck, Simone Marnitz-Schulze, Matthias Miederer, Michael Mix, Nils H. Nicolay, Maximilian Niyazi, Christoph Pöttgen, Claus M. Rödel, Imke Schatka, Sarah M. Schwarzenboeck, Andrei S. Todica, Wolfgang Weber, Simone Wegen, Thomas Wiegel, Constantinos Zamboglou, Daniel Zips, Klaus Zöphel, Sebastian Zschaeck, Daniela Thorwarth, Esther G. C. Troost, MD PhD, Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

This comprehensive review written by experts in their field gives an overview on the current status of incorporating positron emission tomography (PET) into radiation treatment planning. Moreover, it highlights ongoing studies for treatment individualisation and per-treatment tumour response monitoring for various primary tumours. Novel tracers and image analysis methods are discussed. The authors believe this contribution to be of crucial value for experts in the field as well as for policy makers deciding on the reimbursement of this powerful imaging modality.
Literatur
1.
Zurück zum Zitat Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, Yano H, Iwama T (2014) Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-positron emission tomography for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo) 54(4):280–289. https://doi.org/10.2176/nmc.oa2013-0117CrossRef Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, Yano H, Iwama T (2014) Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-positron emission tomography for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo) 54(4):280–289. https://​doi.​org/​10.​2176/​nmc.​oa2013-0117CrossRef
3.
Zurück zum Zitat Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, Gupta DK, Malhotra A, Bal C (2013) 18F‑FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F‑FDG PET/CT. Eur J Nucl Med Mol Imaging 40(7):1025–1035. https://doi.org/10.1007/s00259-013-2384-0PubMedCrossRef Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, Gupta DK, Malhotra A, Bal C (2013) 18F‑FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F‑FDG PET/CT. Eur J Nucl Med Mol Imaging 40(7):1025–1035. https://​doi.​org/​10.​1007/​s00259-013-2384-0PubMedCrossRef
4.
Zurück zum Zitat Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18(9):1199–1208. https://doi.org/10.1093/neuonc/now058PubMedPubMedCentralCrossRef Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18(9):1199–1208. https://​doi.​org/​10.​1093/​neuonc/​now058PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Galldiks N, Langen K‑J, Albert NL, Chamberlain M, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Schwarting J, Combs SE, Preusser M, Forsyth P, Pope W, Weller M, Tonn JC (2019) PET imaging in patients with brain metastasis—Report of the RANO/PET group. Neuro Oncol 21(5):585–595. https://doi.org/10.1093/neuonc/noz003PubMedPubMedCentralCrossRef Galldiks N, Langen K‑J, Albert NL, Chamberlain M, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Schwarting J, Combs SE, Preusser M, Forsyth P, Pope W, Weller M, Tonn JC (2019) PET imaging in patients with brain metastasis—Report of the RANO/PET group. Neuro Oncol 21(5):585–595. https://​doi.​org/​10.​1093/​neuonc/​noz003PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller H‑W, Zilles K, Coenen HH, Langen K‑J (2005) O‑(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(3):678–687. https://doi.org/10.1093/brain/awh399PubMedCrossRef Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller H‑W, Zilles K, Coenen HH, Langen K‑J (2005) O‑(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(3):678–687. https://​doi.​org/​10.​1093/​brain/​awh399PubMedCrossRef
9.
Zurück zum Zitat Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18F‑DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 15(8):1058–1067. https://doi.org/10.1093/neuonc/not002PubMedPubMedCentralCrossRef Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18F‑DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 15(8):1058–1067. https://​doi.​org/​10.​1093/​neuonc/​not002PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Roodakker KR, Alhuseinalkhudhur A, Al-Jaff M, Georganaki M, Zetterling M, Berntsson SG, Danfors T, Strand R, Edqvist P‑H, Dimberg A, Larsson E‑M, Smits A (2019) Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity. Eur J Nucl Med Mol Imaging 46(3):569–579. https://doi.org/10.1007/s00259-018-4107-zPubMedCrossRef Roodakker KR, Alhuseinalkhudhur A, Al-Jaff M, Georganaki M, Zetterling M, Berntsson SG, Danfors T, Strand R, Edqvist P‑H, Dimberg A, Larsson E‑M, Smits A (2019) Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity. Eur J Nucl Med Mol Imaging 46(3):569–579. https://​doi.​org/​10.​1007/​s00259-018-4107-zPubMedCrossRef
11.
Zurück zum Zitat Verburg N, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, Pouwels PJW, Reijneveld JC, Heimans JJ, Rozemuller AJM, Bruynzeel AME, Lagerwaard F, Vandertop WP, Boellaard R, Wesseling P, de Witt Hamer PC (2019) Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro-Oncology 22(3):412–422. https://doi.org/10.1093/neuonc/noz180PubMedCentralCrossRef Verburg N, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, Pouwels PJW, Reijneveld JC, Heimans JJ, Rozemuller AJM, Bruynzeel AME, Lagerwaard F, Vandertop WP, Boellaard R, Wesseling P, de Witt Hamer PC (2019) Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro-Oncology 22(3):412–422. https://​doi.​org/​10.​1093/​neuonc/​noz180PubMedCentralCrossRef
12.
Zurück zum Zitat Schön SCJ, Liesche-Starnecker F, Molina-Romero M, Eichinger P, Metz M, Karimov I, Preibisch C, Keupp J, Hock A, Meyer B, Weber W, Zimmer C, Pyka T, Yakushev I, Gempt J, Wiestler B (2020) Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging 47(6):1468–1475. https://doi.org/10.1007/s00259-019-04677-xPubMedPubMedCentralCrossRef Schön SCJ, Liesche-Starnecker F, Molina-Romero M, Eichinger P, Metz M, Karimov I, Preibisch C, Keupp J, Hock A, Meyer B, Weber W, Zimmer C, Pyka T, Yakushev I, Gempt J, Wiestler B (2020) Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging 47(6):1468–1475. https://​doi.​org/​10.​1007/​s00259-019-04677-xPubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Grosu A‑L, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester H‑J, Weber WA (2011) An interindividual comparison of O‑(2- [18F]Fluoroethyl)-L-Tyrosine (FET)- and L‑[methyl-11C]Methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol 81(4):1049–1058. https://doi.org/10.1016/j.ijrobp.2010.07.002CrossRef Grosu A‑L, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester H‑J, Weber WA (2011) An interindividual comparison of O‑(2- [18F]Fluoroethyl)-L-Tyrosine (FET)- and L‑[methyl-11C]Methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol 81(4):1049–1058. https://​doi.​org/​10.​1016/​j.​ijrobp.​2010.​07.​002CrossRef
16.
Zurück zum Zitat Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, Nestle U, Bock M, Yuh WTC, Meyer PT, Weber WA, Urbach H, Mader I, Grosu A‑L (2019) Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiother Oncol 130:121–131. https://doi.org/10.1016/j.radonc.2018.08.019PubMedCrossRef Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, Nestle U, Bock M, Yuh WTC, Meyer PT, Weber WA, Urbach H, Mader I, Grosu A‑L (2019) Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiother Oncol 130:121–131. https://​doi.​org/​10.​1016/​j.​radonc.​2018.​08.​019PubMedCrossRef
17.
Zurück zum Zitat Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511–519. https://doi.org/10.1016/j.ijrobp.2005.01.056PubMedCrossRef Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511–519. https://​doi.​org/​10.​1016/​j.​ijrobp.​2005.​01.​056PubMedCrossRef
18.
Zurück zum Zitat Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Götz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu A‑L (2016) Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA)—Protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer 16(1):769. https://doi.org/10.1186/s12885-016-2806-zPubMedPubMedCentralCrossRef Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Götz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG, Short SC, Meyer PT, Weber WA, Grosu A‑L (2016) Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA)—Protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer 16(1):769. https://​doi.​org/​10.​1186/​s12885-016-2806-zPubMedPubMedCentralCrossRef
20.
21.
Zurück zum Zitat Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, Schichor C, Rominger A, Albert NL, Bartenstein P, Reiser MF, Cyran CC (2017) Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med 58(10):1580. https://doi.org/10.2967/jnumed.117.191932PubMedCrossRef Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, Schichor C, Rominger A, Albert NL, Bartenstein P, Reiser MF, Cyran CC (2017) Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med 58(10):1580. https://​doi.​org/​10.​2967/​jnumed.​117.​191932PubMedCrossRef
23.
Zurück zum Zitat Spence AM, Muzi M, Graham MM, O’Sullivan F, Link JM, Lewellen TK, Lewellen B, Freeman SD, Mankoff DA, Eary JF, Krohn KA (2002) 2‑[18F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy. Clin Cancer Res 8(4):971PubMed Spence AM, Muzi M, Graham MM, O’Sullivan F, Link JM, Lewellen TK, Lewellen B, Freeman SD, Mankoff DA, Eary JF, Krohn KA (2002) 2‑[18F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy. Clin Cancer Res 8(4):971PubMed
24.
Zurück zum Zitat Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, Newlands ES, Swindell R, Matthews J, Price P (2006) Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 66(2):331–338. https://doi.org/10.1016/j.ijrobp.2006.04.043PubMedCrossRef Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, Newlands ES, Swindell R, Matthews J, Price P (2006) Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 66(2):331–338. https://​doi.​org/​10.​1016/​j.​ijrobp.​2006.​04.​043PubMedCrossRef
25.
Zurück zum Zitat Galldiks N, Langen K‑J, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD (2012) Assessment of treatment response in patients with glioblastoma using O‑(2-18F-Fluoroethyl)-l-tyrosine PET in comparison to MRI. J Nucl Med 53(7):1048. https://doi.org/10.2967/jnumed.111.098590PubMedCrossRef Galldiks N, Langen K‑J, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD (2012) Assessment of treatment response in patients with glioblastoma using O‑(2-18F-Fluoroethyl)-l-tyrosine PET in comparison to MRI. J Nucl Med 53(7):1048. https://​doi.​org/​10.​2967/​jnumed.​111.​098590PubMedCrossRef
26.
28.
Zurück zum Zitat Miller S, Li P, Schipper M, Junck L, Piert M, Lawrence TS, Tsien C, Cao Y, Kim MM (2020) Metabolic tumor volume response assessment using (11) C‑methionine positron emission tomography identifies glioblastoma tumor subregions that predict progression better than baseline or anatomic magnetic resonance imaging alone. Adv Radiat Oncol 5(1):53–61. https://doi.org/10.1016/j.adro.2019.08.004PubMedCrossRef Miller S, Li P, Schipper M, Junck L, Piert M, Lawrence TS, Tsien C, Cao Y, Kim MM (2020) Metabolic tumor volume response assessment using (11) C‑methionine positron emission tomography identifies glioblastoma tumor subregions that predict progression better than baseline or anatomic magnetic resonance imaging alone. Adv Radiat Oncol 5(1):53–61. https://​doi.​org/​10.​1016/​j.​adro.​2019.​08.​004PubMedCrossRef
29.
Zurück zum Zitat Fleischmann DF, Unterrainer M, Bartenstein P, Belka C, Albert NL, Niyazi M (2017) (18)F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images? J Neurooncol 132(2):277–286. https://doi.org/10.1007/s11060-016-2366-8PubMedCrossRef Fleischmann DF, Unterrainer M, Bartenstein P, Belka C, Albert NL, Niyazi M (2017) (18)F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images? J Neurooncol 132(2):277–286. https://​doi.​org/​10.​1007/​s11060-016-2366-8PubMedCrossRef
33.
Zurück zum Zitat Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen K‑J (2015) The use of dynamic O‑(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology 17(9):1293–1300. https://doi.org/10.1093/neuonc/nov088PubMedPubMedCentralCrossRef Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen K‑J (2015) The use of dynamic O‑(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology 17(9):1293–1300. https://​doi.​org/​10.​1093/​neuonc/​nov088PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Werner J‑M, Stoffels G, Lichtenstein T, Borggrefe J, Lohmann P, Ceccon G, Shah NJ, Fink GR, Langen K‑J, Kabbasch C, Galldiks N (2019) Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. Eur J Nucl Med Mol Imaging 46(9):1889–1901. https://doi.org/10.1007/s00259-019-04384-7PubMedCrossRef Werner J‑M, Stoffels G, Lichtenstein T, Borggrefe J, Lohmann P, Ceccon G, Shah NJ, Fink GR, Langen K‑J, Kabbasch C, Galldiks N (2019) Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. Eur J Nucl Med Mol Imaging 46(9):1889–1901. https://​doi.​org/​10.​1007/​s00259-019-04384-7PubMedCrossRef
37.
Zurück zum Zitat Chatterjee S, Frew J, Mott J, McCallum H, Stevenson P, Maxwell R, Wilsdon J, Kelly CG (2012) Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy hi art machine: final results of the VortigERN study. Clin Oncol 24(10):e173–e179. https://doi.org/10.1016/j.clon.2012.09.004CrossRef Chatterjee S, Frew J, Mott J, McCallum H, Stevenson P, Maxwell R, Wilsdon J, Kelly CG (2012) Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy hi art machine: final results of the VortigERN study. Clin Oncol 24(10):e173–e179. https://​doi.​org/​10.​1016/​j.​clon.​2012.​09.​004CrossRef
39.
43.
Zurück zum Zitat Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M (2017) Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Radiother Oncol 124(3):533–540. https://doi.org/10.1016/j.radonc.2017.08.010PubMedCrossRef Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M (2017) Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Radiother Oncol 124(3):533–540. https://​doi.​org/​10.​1016/​j.​radonc.​2017.​08.​010PubMedCrossRef
44.
Zurück zum Zitat Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J (2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 105(1):14–20. https://doi.org/10.1016/j.radonc.2012.09.015PubMedCrossRef Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J (2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 105(1):14–20. https://​doi.​org/​10.​1016/​j.​radonc.​2012.​09.​015PubMedCrossRef
45.
Zurück zum Zitat Troost EGC, Laverman P, Philippens MEP, Lok J, van der Kogel AJ, Oyen WJG, Boerman OC, Kaanders JHAM, Bussink J (2008) Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 35(10):1803–1811. https://doi.org/10.1007/s00259-008-0772-7PubMedCrossRef Troost EGC, Laverman P, Philippens MEP, Lok J, van der Kogel AJ, Oyen WJG, Boerman OC, Kaanders JHAM, Bussink J (2008) Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 35(10):1803–1811. https://​doi.​org/​10.​1007/​s00259-008-0772-7PubMedCrossRef
46.
47.
Zurück zum Zitat Grosu A‑L, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, Wester H‑J, Reischl G, Machulla H‑J, Schwaiger M, Molls M, Piert M (2007) Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 69(2):541–551. https://doi.org/10.1016/j.ijrobp.2007.05.079PubMedCrossRef Grosu A‑L, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, Wester H‑J, Reischl G, Machulla H‑J, Schwaiger M, Molls M, Piert M (2007) Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 69(2):541–551. https://​doi.​org/​10.​1016/​j.​ijrobp.​2007.​05.​079PubMedCrossRef
48.
Zurück zum Zitat Wiedenmann N, Grosu A‑L, Büchert M, Rischke HC, Ruf J, Bielak L, Majerus L, Rühle A, Bamberg F, Baltas D, Hennig J, Mix M, Bock M, Nicolay NH (2020) The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. Radiother Oncol 150:128–135. https://doi.org/10.1016/j.radonc.2020.06.013PubMedCrossRef Wiedenmann N, Grosu A‑L, Büchert M, Rischke HC, Ruf J, Bielak L, Majerus L, Rühle A, Bamberg F, Baltas D, Hennig J, Mix M, Bock M, Nicolay NH (2020) The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. Radiother Oncol 150:128–135. https://​doi.​org/​10.​1016/​j.​radonc.​2020.​06.​013PubMedCrossRef
49.
Zurück zum Zitat Nicolay NH, Wiedenmann N, Mix M, Weber WA, Werner M, Grosu AL, Kayser G (2020) Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—Results from a prospective trial. Eur J Nucl Med Mol Imaging 47(5):1046–1055. https://doi.org/10.1007/s00259-019-04598-9PubMedCrossRef Nicolay NH, Wiedenmann N, Mix M, Weber WA, Werner M, Grosu AL, Kayser G (2020) Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—Results from a prospective trial. Eur J Nucl Med Mol Imaging 47(5):1046–1055. https://​doi.​org/​10.​1007/​s00259-019-04598-9PubMedCrossRef
50.
Zurück zum Zitat Rühle A, Grosu A‑L, Wiedenmann N, Mix M, Stoian R, Niedermann G, Baltas D, Werner M, Weber WA, Kayser G, Nicolay NH (2020) Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with head-and-neck squamous cell carcinoma undergoing chemoradiation. Theranostics 10(20):9395–9406. https://doi.org/10.7150/thno.48392PubMedPubMedCentralCrossRef Rühle A, Grosu A‑L, Wiedenmann N, Mix M, Stoian R, Niedermann G, Baltas D, Werner M, Weber WA, Kayser G, Nicolay NH (2020) Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with head-and-neck squamous cell carcinoma undergoing chemoradiation. Theranostics 10(20):9395–9406. https://​doi.​org/​10.​7150/​thno.​48392PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Riaz N, Sherman E, Pei X, Schöder H, Grkovski M, Paudyal R, Katabi N, Selenica P, Yamaguchi TN, Ma D, Lee SK, Shah R, Kumar R, Kuo F, Ratnakumar A, Aleynick N, Brown D, Zhang Z, Hatzoglou V, Liu LY, Salcedo A, Tsai CJ, McBride S, Morris LGT, Boyle J, Singh B, Higginson DS, Damerla RR, Paula AC, Price K, Moore EJ, Garcia JJ, Foote R, Ho A, Wong RJ, Chan TA, Powell SN, Boutros PC, Humm JL, Shukla-Dave A, Pfister D, Reis-Filho JS, Lee N (2021) Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa184PubMedCrossRefPubMedCentral Riaz N, Sherman E, Pei X, Schöder H, Grkovski M, Paudyal R, Katabi N, Selenica P, Yamaguchi TN, Ma D, Lee SK, Shah R, Kumar R, Kuo F, Ratnakumar A, Aleynick N, Brown D, Zhang Z, Hatzoglou V, Liu LY, Salcedo A, Tsai CJ, McBride S, Morris LGT, Boyle J, Singh B, Higginson DS, Damerla RR, Paula AC, Price K, Moore EJ, Garcia JJ, Foote R, Ho A, Wong RJ, Chan TA, Powell SN, Boutros PC, Humm JL, Shukla-Dave A, Pfister D, Reis-Filho JS, Lee N (2021) Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial. J Natl Cancer Inst. https://​doi.​org/​10.​1093/​jnci/​djaa184PubMedCrossRefPubMedCentral
54.
Zurück zum Zitat Troost EGC, Vogel WV, Merkx MAW, Slootweg PJ, Marres HAM, Peeters WJM, Bussink J, van der Kogel AJ, Oyen WJG, Kaanders JHAM (2007) 18F‑FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48(5):726. https://doi.org/10.2967/jnumed.106.037473PubMedCrossRef Troost EGC, Vogel WV, Merkx MAW, Slootweg PJ, Marres HAM, Peeters WJM, Bussink J, van der Kogel AJ, Oyen WJG, Kaanders JHAM (2007) 18F‑FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48(5):726. https://​doi.​org/​10.​2967/​jnumed.​106.​037473PubMedCrossRef
55.
Zurück zum Zitat Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, Koerber SA, Freudlsperger C, Plinkert PK, Debus J, Giesel F, Haberkorn U, Adeberg S (2020) Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging 47(12):2836–2845. https://doi.org/10.1007/s00259-020-04859-yPubMedPubMedCentralCrossRef Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S, Koerber SA, Freudlsperger C, Plinkert PK, Debus J, Giesel F, Haberkorn U, Adeberg S (2020) Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging 47(12):2836–2845. https://​doi.​org/​10.​1007/​s00259-020-04859-yPubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Machado Medeiros T, Altmayer S, Watte G, Zanon M, Basso Dias A, Henz Concatto N, Hoefel Paes J, Mattiello R, de Souza Santos F, Mohammed T‑L, Verma N, Hochhegger B (2020) 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Eur Radiol 30(7):3641–3649. https://doi.org/10.1007/s00330-020-06703-1PubMedCrossRef Machado Medeiros T, Altmayer S, Watte G, Zanon M, Basso Dias A, Henz Concatto N, Hoefel Paes J, Mattiello R, de Souza Santos F, Mohammed T‑L, Verma N, Hochhegger B (2020) 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Eur Radiol 30(7):3641–3649. https://​doi.​org/​10.​1007/​s00330-020-06703-1PubMedCrossRef
58.
Zurück zum Zitat Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel Y‑P, Hass P, Fleckenstein J, Thieme A, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Gkika E, Adebahr S, König J, Grosu A‑L (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol 21(4):581–592. https://doi.org/10.1016/S1470-2045(20)30013-9PubMedCrossRef Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel Y‑P, Hass P, Fleckenstein J, Thieme A, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Gkika E, Adebahr S, König J, Grosu A‑L (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol 21(4):581–592. https://​doi.​org/​10.​1016/​S1470-2045(20)30013-9PubMedCrossRef
60.
Zurück zum Zitat Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePéchoux C, Van Houtte P (2018) ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 127(1):1–5. https://doi.org/10.1016/j.radonc.2018.02.023PubMedCrossRef Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePéchoux C, Van Houtte P (2018) ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 127(1):1–5. https://​doi.​org/​10.​1016/​j.​radonc.​2018.​02.​023PubMedCrossRef
61.
Zurück zum Zitat Kong F‑M, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T, Bi N, Wang W, Orringer M, Cease KB, Lawrence TS, Kalemkerian GP (2017) Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol 3(10):1358–1365. https://doi.org/10.1001/jamaoncol.2017.0982PubMedPubMedCentralCrossRef Kong F‑M, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, Ramnath N, Hassan KA, Matuszak M, Ritter T, Bi N, Wang W, Orringer M, Cease KB, Lawrence TS, Kalemkerian GP (2017) Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol 3(10):1358–1365. https://​doi.​org/​10.​1001/​jamaoncol.​2017.​0982PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, Heinzelmann F, Cordes S, Schuler MH, Welter S, Stamatis G, Friedel G, Darwiche K, Jöckel K‑H, Eberhardt W, Stuschke M (2016) Standardized uptake decrease on [18F]-Fluorodeoxyglucose positron emission tomography after Neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for resectable stage IIIA/B non-small-cell lung cancer. J Clin Oncol 34(21):2526–2533. https://doi.org/10.1200/jco.2015.65.5167PubMedCrossRef Pöttgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, Heinzelmann F, Cordes S, Schuler MH, Welter S, Stamatis G, Friedel G, Darwiche K, Jöckel K‑H, Eberhardt W, Stuschke M (2016) Standardized uptake decrease on [18F]-Fluorodeoxyglucose positron emission tomography after Neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for resectable stage IIIA/B non-small-cell lung cancer. J Clin Oncol 34(21):2526–2533. https://​doi.​org/​10.​1200/​jco.​2015.​65.​5167PubMedCrossRef
64.
Zurück zum Zitat Dissaux G, Visvikis D, Da-ano R, Pradier O, Chajon E, Barillot I, Duvergé L, Masson I, Abgral R, Santiago Ribeiro M‑J, Devillers A, Pallardy A, Fleury V, Mahé M‑A, De Crevoisier R, Hatt M, Schick U (2020) Pretreatment 18F‑FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study. J Nucl Med 61(6):814. https://doi.org/10.2967/jnumed.119.228106PubMedCrossRef Dissaux G, Visvikis D, Da-ano R, Pradier O, Chajon E, Barillot I, Duvergé L, Masson I, Abgral R, Santiago Ribeiro M‑J, Devillers A, Pallardy A, Fleury V, Mahé M‑A, De Crevoisier R, Hatt M, Schick U (2020) Pretreatment 18F‑FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study. J Nucl Med 61(6):814. https://​doi.​org/​10.​2967/​jnumed.​119.​228106PubMedCrossRef
66.
Zurück zum Zitat Bissonnette J‑P, Yap ML, Clarke K, Shessel A, Higgins J, Vines D, Atenafu EG, Becker N, Leavens C, Bezjak A, Jaffray DA, Sun A (2018) Serial 4DCT/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy. Radiother Oncol 126(2):347–354. https://doi.org/10.1016/j.radonc.2017.11.023PubMedCrossRef Bissonnette J‑P, Yap ML, Clarke K, Shessel A, Higgins J, Vines D, Atenafu EG, Becker N, Leavens C, Bezjak A, Jaffray DA, Sun A (2018) Serial 4DCT/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy. Radiother Oncol 126(2):347–354. https://​doi.​org/​10.​1016/​j.​radonc.​2017.​11.​023PubMedCrossRef
70.
Zurück zum Zitat Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, Tufman A, Huber RM, Belka C, Manapov F (2018) Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. Strahlenther Onkol 194(2):107–115. https://doi.org/10.1007/s00066-017-1229-3PubMedCrossRef Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, Tufman A, Huber RM, Belka C, Manapov F (2018) Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. Strahlenther Onkol 194(2):107–115. https://​doi.​org/​10.​1007/​s00066-017-1229-3PubMedCrossRef
72.
Zurück zum Zitat Duan C, Chaovalitwongse WA, Bai F, Hippe DS, Wang S, Thammasorn P, Pierce LA, Liu X, You J, Miyaoka RS, Vesselle HJ, Kinahan PE, Rengan R, Zeng J, Bowen SR (2020) Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer. Phys Med Biol 65(20):205007. https://doi.org/10.1088/1361-6560/abb0c7PubMedCrossRefPubMedCentral Duan C, Chaovalitwongse WA, Bai F, Hippe DS, Wang S, Thammasorn P, Pierce LA, Liu X, You J, Miyaoka RS, Vesselle HJ, Kinahan PE, Rengan R, Zeng J, Bowen SR (2020) Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer. Phys Med Biol 65(20):205007. https://​doi.​org/​10.​1088/​1361-6560/​abb0c7PubMedCrossRefPubMedCentral
74.
Zurück zum Zitat Bollineni VR, Kerner GSMA, Pruim J, Steenbakkers RJHM, Wiegman EM, Koole MJB, de Groot EH, Willemsen ATM, Luurtsema G, Widder J, Groen HJM, Langendijk JA (2013) PET imaging of tumor hypoxia using 18F‑Fluoroazomycin arabinoside in stage III–IV non-small cell lung cancer patients. J Nucl Med 54(8):1175. https://doi.org/10.2967/jnumed.112.115014PubMedCrossRef Bollineni VR, Kerner GSMA, Pruim J, Steenbakkers RJHM, Wiegman EM, Koole MJB, de Groot EH, Willemsen ATM, Luurtsema G, Widder J, Groen HJM, Langendijk JA (2013) PET imaging of tumor hypoxia using 18F‑Fluoroazomycin arabinoside in stage III–IV non-small cell lung cancer patients. J Nucl Med 54(8):1175. https://​doi.​org/​10.​2967/​jnumed.​112.​115014PubMedCrossRef
75.
Zurück zum Zitat Bollineni VR, Koole MJB, Pruim J, Brouwer CL, Wiegman EM, Groen HJM, Vlasman R, Halmos GB, Oosting SF, Langendijk JA, Widder J, Steenbakkers RJHM (2014) Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol 113(2):198–203. https://doi.org/10.1016/j.radonc.2014.10.010PubMedCrossRef Bollineni VR, Koole MJB, Pruim J, Brouwer CL, Wiegman EM, Groen HJM, Vlasman R, Halmos GB, Oosting SF, Langendijk JA, Widder J, Steenbakkers RJHM (2014) Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol 113(2):198–203. https://​doi.​org/​10.​1016/​j.​radonc.​2014.​10.​010PubMedCrossRef
76.
Zurück zum Zitat Everitt S, Ball D, Hicks RJ, Callahan J, Plumridge N, Trinh J, Herschtal A, Kron T, Mac Manus M (2017) Prospective study of serial imaging comparing fluorodeoxyglucose positron emission tomography (PET) and fluorothymidine PET during radical Chemoradiation for non-small cell lung cancer: reduction of detectable proliferation associated with worse survival. Int J Radiat Oncol Biol Phys 99(4):947–955. https://doi.org/10.1016/j.ijrobp.2017.07.035PubMedCrossRef Everitt S, Ball D, Hicks RJ, Callahan J, Plumridge N, Trinh J, Herschtal A, Kron T, Mac Manus M (2017) Prospective study of serial imaging comparing fluorodeoxyglucose positron emission tomography (PET) and fluorothymidine PET during radical Chemoradiation for non-small cell lung cancer: reduction of detectable proliferation associated with worse survival. Int J Radiat Oncol Biol Phys 99(4):947–955. https://​doi.​org/​10.​1016/​j.​ijrobp.​2017.​07.​035PubMedCrossRef
77.
Zurück zum Zitat Everitt SJ, Ball DL, Hicks RJ, Callahan J, Plumridge N, Collins M, Herschtal A, Binns D, Kron T, Schneider M, MacManus M (2014) Differential (18)F-FDG and (18)F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. J Nucl Med 55(7):1069–1074. https://doi.org/10.2967/jnumed.113.131631PubMedCrossRef Everitt SJ, Ball DL, Hicks RJ, Callahan J, Plumridge N, Collins M, Herschtal A, Binns D, Kron T, Schneider M, MacManus M (2014) Differential (18)F-FDG and (18)F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. J Nucl Med 55(7):1069–1074. https://​doi.​org/​10.​2967/​jnumed.​113.​131631PubMedCrossRef
78.
Zurück zum Zitat Kairemo K, Santos EB, Macapinlac HA, Subbiah V (2020) Early response assessment to targeted therapy using 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT in lung cancer. Diagnostics 10(1):26PubMedCentralCrossRef Kairemo K, Santos EB, Macapinlac HA, Subbiah V (2020) Early response assessment to targeted therapy using 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT in lung cancer. Diagnostics 10(1):26PubMedCentralCrossRef
79.
Zurück zum Zitat Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA (2019) Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. 17(7):855. https://doi.org/10.6004/jnccn.2019.0033 Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA (2019) Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. 17(7):855. https://​doi.​org/​10.​6004/​jnccn.​2019.​0033
81.
Zurück zum Zitat Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25(10):1160–1168. https://doi.org/10.1200/jco.2005.04.7118CrossRefPubMed Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25(10):1160–1168. https://​doi.​org/​10.​1200/​jco.​2005.​04.​7118CrossRefPubMed
82.
Zurück zum Zitat Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23(10):2310–2317. https://doi.org/10.1200/jco.2005.00.034CrossRefPubMed Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23(10):2310–2317. https://​doi.​org/​10.​1200/​jco.​2005.​00.​034CrossRefPubMed
83.
Zurück zum Zitat van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIB, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers G‑J, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://doi.org/10.1056/NEJMoa1112088CrossRefPubMed van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIB, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers G‑J, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://​doi.​org/​10.​1056/​NEJMoa1112088CrossRefPubMed
84.
Zurück zum Zitat Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Aleman BMP, Nijkamp J, Meijer GJ, Lips IM (2019) Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: a nationwide study. Clin Transl Radiat Oncol 14:33–39. https://doi.org/10.1016/j.ctro.2018.10.003PubMedCrossRef Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Aleman BMP, Nijkamp J, Meijer GJ, Lips IM (2019) Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: a nationwide study. Clin Transl Radiat Oncol 14:33–39. https://​doi.​org/​10.​1016/​j.​ctro.​2018.​10.​003PubMedCrossRef
86.
Zurück zum Zitat Thomas M, Mortensen HR, Hoffmann L, Møller DS, Troost EGC, Muijs CT, Berbee M, Bütof R, Nicholas O, Radhakrishna G, Defraene G, Nafteux P, Nordsmark M, Haustermans K (2021) Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiother Oncol 156:102–112. https://doi.org/10.1016/j.radonc.2020.11.032PubMedCrossRef Thomas M, Mortensen HR, Hoffmann L, Møller DS, Troost EGC, Muijs CT, Berbee M, Bütof R, Nicholas O, Radhakrishna G, Defraene G, Nafteux P, Nordsmark M, Haustermans K (2021) Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiother Oncol 156:102–112. https://​doi.​org/​10.​1016/​j.​radonc.​2020.​11.​032PubMedCrossRef
89.
90.
91.
Zurück zum Zitat Li Y, Beck M, Päßler T, Lili C, Hua W, Mai HD, Amthauer H, Biebl M, Thuss-Patience PC, Berger J, Stromberger C, Tinhofer I, Kruppa J, Budach V, Hofheinz F, Lin Q, Zschaeck S (2020) A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation. Sci Rep 10(1):17671. https://doi.org/10.1038/s41598-020-74701-wPubMedPubMedCentralCrossRef Li Y, Beck M, Päßler T, Lili C, Hua W, Mai HD, Amthauer H, Biebl M, Thuss-Patience PC, Berger J, Stromberger C, Tinhofer I, Kruppa J, Budach V, Hofheinz F, Lin Q, Zschaeck S (2020) A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation. Sci Rep 10(1):17671. https://​doi.​org/​10.​1038/​s41598-020-74701-wPubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Zschaeck S, Hofheinz F, Zöphel K, Bütof R, Jentsch C, Schmollack J, Löck S, Kotzerke J, Baretton G, Weitz J, Baumann M, Krause M (2017) Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 44(11):1813–1822. https://doi.org/10.1007/s00259-017-3742-0PubMedCrossRef Zschaeck S, Hofheinz F, Zöphel K, Bütof R, Jentsch C, Schmollack J, Löck S, Kotzerke J, Baretton G, Weitz J, Baumann M, Krause M (2017) Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 44(11):1813–1822. https://​doi.​org/​10.​1007/​s00259-017-3742-0PubMedCrossRef
93.
Zurück zum Zitat Zschaeck S, Li Y, Bütof R, Lili C, Hua W, Troost ECG, Beck M, Amthauer H, Kaul D, Kotzerke J, Baur ADJ, Ghadjar P, Baumann M, Krause M, Hofheinz F (2020) Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. Int J Cancer 147(5):1427–1436. https://doi.org/10.1002/ijc.32897PubMedCrossRef Zschaeck S, Li Y, Bütof R, Lili C, Hua W, Troost ECG, Beck M, Amthauer H, Kaul D, Kotzerke J, Baur ADJ, Ghadjar P, Baumann M, Krause M, Hofheinz F (2020) Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. Int J Cancer 147(5):1427–1436. https://​doi.​org/​10.​1002/​ijc.​32897PubMedCrossRef
94.
Zurück zum Zitat Kroese TE, Goense L, van Hillegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN (2018) Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Dis Esophagus. https://doi.org/10.1093/dote/doy055PubMedCrossRef Kroese TE, Goense L, van Hillegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN (2018) Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Dis Esophagus. https://​doi.​org/​10.​1093/​dote/​doy055PubMedCrossRef
95.
Zurück zum Zitat Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB, Doukas M, Krak NC, Poley J‑W, van Rij CM, Bergman JJ, Gisbertz SS, van Laarhoven HWM, Meijer SL, Goense L, Haj Mohammad N, Hobbelink MGG, Offerhaus GJA, Vleggaar F, Curvers WL, Creemers G‑J, Roef MJ, van der Sangen MJC, Buijsen J, Riedl RG, Schreurs WMJ, Warmerdam FARM, Janssen MJR, van der Post C, Radema SA, Rosman C, Rütten H (2018) Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 19(7):965–974. https://doi.org/10.1016/S1470-2045(18)30201-8PubMedCrossRef Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB, Doukas M, Krak NC, Poley J‑W, van Rij CM, Bergman JJ, Gisbertz SS, van Laarhoven HWM, Meijer SL, Goense L, Haj Mohammad N, Hobbelink MGG, Offerhaus GJA, Vleggaar F, Curvers WL, Creemers G‑J, Roef MJ, van der Sangen MJC, Buijsen J, Riedl RG, Schreurs WMJ, Warmerdam FARM, Janssen MJR, van der Post C, Radema SA, Rosman C, Rütten H (2018) Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 19(7):965–974. https://​doi.​org/​10.​1016/​S1470-2045(18)30201-8PubMedCrossRef
96.
Zurück zum Zitat Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, Martin JM, Burge M, Finch R, Karapetis CS, Shannon J, Nott LM, Varma S, Marx G, Falk GL, Gebski V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcberg JR, Simes J, Smithers BM (2020) Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. Ann Oncol 31(2):236–245. https://doi.org/10.1016/j.annonc.2019.10.019PubMedCrossRef Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, Martin JM, Burge M, Finch R, Karapetis CS, Shannon J, Nott LM, Varma S, Marx G, Falk GL, Gebski V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcberg JR, Simes J, Smithers BM (2020) Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. Ann Oncol 31(2):236–245. https://​doi.​org/​10.​1016/​j.​annonc.​2019.​10.​019PubMedCrossRef
98.
Zurück zum Zitat Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, Sebag-Montefiore D, Tekkis P, Brown G (2014) Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5‑year follow-up results of the MERCURY study. J Clin Oncol 32(1):34–43. https://doi.org/10.1200/jco.2012.45.3258PubMedCrossRef Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, Sebag-Montefiore D, Tekkis P, Brown G (2014) Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5‑year follow-up results of the MERCURY study. J Clin Oncol 32(1):34–43. https://​doi.​org/​10.​1200/​jco.​2012.​45.​3258PubMedCrossRef
99.
105.
106.
Zurück zum Zitat Maas M, Lambregts DMJ, Nelemans PJ, Heijnen LA, Martens MH, Leijtens JWA, Sosef M, Hulsewé KWE, Hoff C, Breukink SO, Stassen L, Beets-Tan RGH, Beets GL (2015) Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 22(12):3873–3880. https://doi.org/10.1245/s10434-015-4687-9PubMedPubMedCentralCrossRef Maas M, Lambregts DMJ, Nelemans PJ, Heijnen LA, Martens MH, Leijtens JWA, Sosef M, Hulsewé KWE, Hoff C, Breukink SO, Stassen L, Beets-Tan RGH, Beets GL (2015) Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 22(12):3873–3880. https://​doi.​org/​10.​1245/​s10434-015-4687-9PubMedPubMedCentralCrossRef
109.
Zurück zum Zitat Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299(16):1914–1921. https://doi.org/10.1001/jama.299.16.1914PubMedCrossRef Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299(16):1914–1921. https://​doi.​org/​10.​1001/​jama.​299.​16.​1914PubMedCrossRef
110.
Zurück zum Zitat James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol 14(6):516–524. https://doi.org/10.1016/S1470-2045(13)70086-XPubMedCrossRef James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol 14(6):516–524. https://​doi.​org/​10.​1016/​S1470-2045(13)70086-XPubMedCrossRef
112.
113.
Zurück zum Zitat Mistrangelo M, Pelosi E, Bellò M, Ricardi U, Milanesi E, Cassoni P, Baccega M, Filippini C, Racca P, Lesca A, Munoz FH, Fora G, Skanjeti A, Cravero F, Morino M (2012) Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 84(1):66–72. https://doi.org/10.1016/j.ijrobp.2011.10.048PubMedCrossRef Mistrangelo M, Pelosi E, Bellò M, Ricardi U, Milanesi E, Cassoni P, Baccega M, Filippini C, Racca P, Lesca A, Munoz FH, Fora G, Skanjeti A, Cravero F, Morino M (2012) Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 84(1):66–72. https://​doi.​org/​10.​1016/​j.​ijrobp.​2011.​10.​048PubMedCrossRef
123.
Zurück zum Zitat Reginelli A, Granata V, Fusco R, Granata F, Rega D, Roberto L, Pellino G, Rotondo A, Selvaggi F, Izzo F, Petrillo A, Grassi R (2017) Diagnostic performance of magnetic resonance imaging and 3D endoanal ultrasound in detection, staging and assessment post treatment, in anal cancer. Oncotarget 8(14):22980–22990. https://doi.org/10.18632/oncotarget.14946PubMedPubMedCentralCrossRef Reginelli A, Granata V, Fusco R, Granata F, Rega D, Roberto L, Pellino G, Rotondo A, Selvaggi F, Izzo F, Petrillo A, Grassi R (2017) Diagnostic performance of magnetic resonance imaging and 3D endoanal ultrasound in detection, staging and assessment post treatment, in anal cancer. Oncotarget 8(14):22980–22990. https://​doi.​org/​10.​18632/​oncotarget.​14946PubMedPubMedCentralCrossRef
124.
Zurück zum Zitat Catalano OA, Lee SI, Parente C, Cauley C, Furtado FS, Striar R, Soricelli A, Salvatore M, Li Y, Umutlu L, Cañamaque LG, Groshar D, Mahmood U, Blaszkowsky LS, Ryan DP, Clark JW, Wo J, Hong TS, Kunitake H, Bordeianou L, Berger D, Ricciardi R, Rosen B (2020) Improving staging of rectal cancer in the pelvis: the role of PET/MRI. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-020-05036-xPubMedCrossRef Catalano OA, Lee SI, Parente C, Cauley C, Furtado FS, Striar R, Soricelli A, Salvatore M, Li Y, Umutlu L, Cañamaque LG, Groshar D, Mahmood U, Blaszkowsky LS, Ryan DP, Clark JW, Wo J, Hong TS, Kunitake H, Bordeianou L, Berger D, Ricciardi R, Rosen B (2020) Improving staging of rectal cancer in the pelvis: the role of PET/MRI. Eur J Nucl Med Mol Imaging. https://​doi.​org/​10.​1007/​s00259-020-05036-xPubMedCrossRef
126.
Zurück zum Zitat Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, Das P, Gunderson LL, Hong TS, Kim JJJ, Willett CG, Kachnic LA (2009) Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 74(3):824–830. https://doi.org/10.1016/j.ijrobp.2008.08.070PubMedCrossRef Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, Das P, Gunderson LL, Hong TS, Kim JJJ, Willett CG, Kachnic LA (2009) Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 74(3):824–830. https://​doi.​org/​10.​1016/​j.​ijrobp.​2008.​08.​070PubMedCrossRef
127.
Zurück zum Zitat Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan S, Kachnic L (2012) Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol 83(5):1455–1462. https://doi.org/10.1016/j.ijrobp.2011.12.058CrossRef Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan S, Kachnic L (2012) Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol 83(5):1455–1462. https://​doi.​org/​10.​1016/​j.​ijrobp.​2011.​12.​058CrossRef
134.
Zurück zum Zitat Marnitz S, Köhler C, Affonso RJ, Schneider A, Chiantera V, Tsounoda A, Vercellino F (2012) Validity of laparoscopic staging to avoid adjuvant chemoradiation following radical surgery in patients with early cervical cancer. Oncology 83(6):346–353. https://doi.org/10.1159/000341659PubMedCrossRef Marnitz S, Köhler C, Affonso RJ, Schneider A, Chiantera V, Tsounoda A, Vercellino F (2012) Validity of laparoscopic staging to avoid adjuvant chemoradiation following radical surgery in patients with early cervical cancer. Oncology 83(6):346–353. https://​doi.​org/​10.​1159/​000341659PubMedCrossRef
136.
Zurück zum Zitat Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, Uzan C, Lumbroso S, Lecuru F, Bats AS, Ghazzar N, Bannier M, Houvenaeghel G, Brenot-Rossi I, Narducci F (2011) Accuracy of 18-Fluoro-2-deoxy-d-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. Ann Surg Oncol 18(8):2302–2309. https://doi.org/10.1245/s10434-011-1583-9PubMedCrossRef Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, Uzan C, Lumbroso S, Lecuru F, Bats AS, Ghazzar N, Bannier M, Houvenaeghel G, Brenot-Rossi I, Narducci F (2011) Accuracy of 18-Fluoro-2-deoxy-d-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. Ann Surg Oncol 18(8):2302–2309. https://​doi.​org/​10.​1245/​s10434-011-1583-9PubMedCrossRef
137.
Zurück zum Zitat Marnitz S, Tsunoda AT, Martus P, Vieira M, Affonso Junior RJ, Nunes J, Budach V, Hertel H, Mustea A, Sehouli J, Scharf J‑P, Ulrich U, Ebert A, Piwonski I, Kohler C (2020) Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study. Int J Gynecol Cancer 30(12):1855–1861. https://doi.org/10.1136/ijgc-2020-001973PubMedPubMedCentralCrossRef Marnitz S, Tsunoda AT, Martus P, Vieira M, Affonso Junior RJ, Nunes J, Budach V, Hertel H, Mustea A, Sehouli J, Scharf J‑P, Ulrich U, Ebert A, Piwonski I, Kohler C (2020) Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study. Int J Gynecol Cancer 30(12):1855–1861. https://​doi.​org/​10.​1136/​ijgc-2020-001973PubMedPubMedCentralCrossRef
138.
Zurück zum Zitat Köhler C, Mustea A, Marnitz S, Schneider A, Chiantera V, Ulrich U, Scharf J‑P, Martus P, Vieira MA, Tsunoda A (2015) Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial. Am J Obstet Gynecol 213(4):503.e1–503.e57. https://doi.org/10.1016/j.ajog.2015.05.026CrossRef Köhler C, Mustea A, Marnitz S, Schneider A, Chiantera V, Ulrich U, Scharf J‑P, Martus P, Vieira MA, Tsunoda A (2015) Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial. Am J Obstet Gynecol 213(4):503.e1–503.e57. https://​doi.​org/​10.​1016/​j.​ajog.​2015.​05.​026CrossRef
139.
Zurück zum Zitat Tsunoda AT, Marnitz S, Soares Nunes J, Mattos de Cunha Andrade CE, Scapulatempo Neto C, Blohmer JU, Herrmann J, Kerr LM, Martus P, Schneider A, Favero G, Köhler C (2017) Incidence of histologically proven pelvic and para-aortic lymph node metastases and rate of upstaging in patients with locally advanced cervical cancer: results of a prospective randomized trial. Oncology 92(4):213–220. https://doi.org/10.1159/000453666PubMedCrossRef Tsunoda AT, Marnitz S, Soares Nunes J, Mattos de Cunha Andrade CE, Scapulatempo Neto C, Blohmer JU, Herrmann J, Kerr LM, Martus P, Schneider A, Favero G, Köhler C (2017) Incidence of histologically proven pelvic and para-aortic lymph node metastases and rate of upstaging in patients with locally advanced cervical cancer: results of a prospective randomized trial. Oncology 92(4):213–220. https://​doi.​org/​10.​1159/​000453666PubMedCrossRef
140.
Zurück zum Zitat Marnitz S, Schram J, Budach V, Sackerer I, Vercellino GF, Sehouli J, Köhler C (2015) Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy. Strahlenther Onkol 191(5):421–428. https://doi.org/10.1007/s00066-014-0785-zPubMedCrossRef Marnitz S, Schram J, Budach V, Sackerer I, Vercellino GF, Sehouli J, Köhler C (2015) Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy. Strahlenther Onkol 191(5):421–428. https://​doi.​org/​10.​1007/​s00066-014-0785-zPubMedCrossRef
141.
Zurück zum Zitat Gouy S, Morice P, Narducci F, Uzan C, Martinez A, Rey A, Bentivegna E, Pautier P, Deandreis D, Querleu D, Haie-Meder C, Leblanc E (2013) Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. J Clin Oncol 31(24):3026–3033. https://doi.org/10.1200/jco.2012.47.3520PubMedCrossRef Gouy S, Morice P, Narducci F, Uzan C, Martinez A, Rey A, Bentivegna E, Pautier P, Deandreis D, Querleu D, Haie-Meder C, Leblanc E (2013) Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. J Clin Oncol 31(24):3026–3033. https://​doi.​org/​10.​1200/​jco.​2012.​47.​3520PubMedCrossRef
142.
Zurück zum Zitat Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, LeBlanc E, Martinez A, Ramirez PT (2014) Lymphadenectomy in locally advanced cervical cancer study (LiLACS): phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2–IVA cervical cancer. J Minim Invasive Gynecol 21(1):3–8. https://doi.org/10.1016/j.jmig.2013.07.007PubMedCrossRef Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, LeBlanc E, Martinez A, Ramirez PT (2014) Lymphadenectomy in locally advanced cervical cancer study (LiLACS): phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2–IVA cervical cancer. J Minim Invasive Gynecol 21(1):3–8. https://​doi.​org/​10.​1016/​j.​jmig.​2013.​07.​007PubMedCrossRef
143.
Zurück zum Zitat Lima GM, Matti A, Vara G, Dondi G, Naselli N, De Crescenzo EM, Morganti AG, Perrone AM, De Iaco P, Nanni C, Fanti S (2018) Prognostic value of posttreatment 18F‑FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. Eur J Nucl Med Mol Imaging 45(12):2139–2146. https://doi.org/10.1007/s00259-018-4077-1PubMedPubMedCentralCrossRef Lima GM, Matti A, Vara G, Dondi G, Naselli N, De Crescenzo EM, Morganti AG, Perrone AM, De Iaco P, Nanni C, Fanti S (2018) Prognostic value of posttreatment 18F‑FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. Eur J Nucl Med Mol Imaging 45(12):2139–2146. https://​doi.​org/​10.​1007/​s00259-018-4077-1PubMedPubMedCentralCrossRef
144.
Zurück zum Zitat Rufini V, Collarino A, Calcagni ML, Meduri GM, Fuoco V, Pasciuto T, Testa AC, Ferrandina G, Gambacorta MA, Campitelli M, Gui B, Zannoni G, Manfredi R, Scambia G, Giordano A (2020) The role of FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study. Eur J Nucl Med Mol Imaging 47(5):1228–1238. https://doi.org/10.1007/s00259-019-04436-yPubMedCrossRef Rufini V, Collarino A, Calcagni ML, Meduri GM, Fuoco V, Pasciuto T, Testa AC, Ferrandina G, Gambacorta MA, Campitelli M, Gui B, Zannoni G, Manfredi R, Scambia G, Giordano A (2020) The role of FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study. Eur J Nucl Med Mol Imaging 47(5):1228–1238. https://​doi.​org/​10.​1007/​s00259-019-04436-yPubMedCrossRef
145.
Zurück zum Zitat Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R, Tongaonkar H, Ghosh J, Gulia S, Kumar N, Shylasree TS, Gawade R, Kembhavi Y, Gaikar M, Menon S, Thakur M, Shrivastava S, Badwe R (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36(16):1548–1555. https://doi.org/10.1200/jco.2017.75.9985CrossRefPubMed Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R, Tongaonkar H, Ghosh J, Gulia S, Kumar N, Shylasree TS, Gawade R, Kembhavi Y, Gaikar M, Menon S, Thakur M, Shrivastava S, Badwe R (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36(16):1548–1555. https://​doi.​org/​10.​1200/​jco.​2017.​75.​9985CrossRefPubMed
146.
Zurück zum Zitat Kenter G, Greggi S, Vergote I, Katsaros D, Kobierski J, Massuger L, van Doorn HC, Landoni F, Velden JVD, Reed NS, Coens C, van Luijk I, Ottevanger PB, Casado A (2019) Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2–IIb cervical cancer, EORTC 55994. J Clin Oncol 37(15_suppl):5503–5503. https://doi.org/10.1200/JCO.2019.37.15_suppl.5503CrossRef Kenter G, Greggi S, Vergote I, Katsaros D, Kobierski J, Massuger L, van Doorn HC, Landoni F, Velden JVD, Reed NS, Coens C, van Luijk I, Ottevanger PB, Casado A (2019) Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2–IIb cervical cancer, EORTC 55994. J Clin Oncol 37(15_suppl):5503–5503. https://​doi.​org/​10.​1200/​JCO.​2019.​37.​15_​suppl.​5503CrossRef
149.
Zurück zum Zitat Zhou Z, Liu X, Hu K, Zhang F (2018) The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence. Nucl Med Commun 39(2):97–102PubMedCrossRef Zhou Z, Liu X, Hu K, Zhang F (2018) The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence. Nucl Med Commun 39(2):97–102PubMedCrossRef
151.
Zurück zum Zitat Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor H‑U, Jäger D, Debus J, Haberkorn U, Giesel FL (2019) 68Ga-FAPI PET/CTa-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60(6):801. https://doi.org/10.2967/jnumed.119.227967PubMedPubMedCentralCrossRef Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor H‑U, Jäger D, Debus J, Haberkorn U, Giesel FL (2019) 68Ga-FAPI PET/CTa-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60(6):801. https://​doi.​org/​10.​2967/​jnumed.​119.​227967PubMedPubMedCentralCrossRef
153.
Zurück zum Zitat Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M (2019) Detection efficacy of 18F‑PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med 60(3):362–368. https://doi.org/10.2967/jnumed.118.212233PubMedPubMedCentralCrossRef Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M (2019) Detection efficacy of 18F‑PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med 60(3):362–368. https://​doi.​org/​10.​2967/​jnumed.​118.​212233PubMedPubMedCentralCrossRef
154.
Zurück zum Zitat Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis ES, Eisenberger MA, Carducci MA, Ross AE, Kantoff PW, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY (2016) Comparison of prostate-specific membrane antigen-based 18F‑DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer. J Nucl Med 57(1):46–53. https://doi.org/10.2967/jnumed.115.163782PubMedCrossRef Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis ES, Eisenberger MA, Carducci MA, Ross AE, Kantoff PW, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY (2016) Comparison of prostate-specific membrane antigen-based 18F‑DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer. J Nucl Med 57(1):46–53. https://​doi.​org/​10.​2967/​jnumed.​115.​163782PubMedCrossRef
155.
Zurück zum Zitat Kroenke M, Mirzoyan L, Horn T, Peeken JC, Wurzer A, Wester H‑J, Makowski M, Weber WA, Eiber M, Rauscher I (2020) Matched-pair comparison of 68Ga-PSMA-11 and 18F‑rhPSMA‑7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor related uptake and tumor positivity. J Nucl Med. https://doi.org/10.2967/jnumed.120.251447PubMedPubMedCentralCrossRef Kroenke M, Mirzoyan L, Horn T, Peeken JC, Wurzer A, Wester H‑J, Makowski M, Weber WA, Eiber M, Rauscher I (2020) Matched-pair comparison of 68Ga-PSMA-11 and 18F‑rhPSMA‑7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor related uptake and tumor positivity. J Nucl Med. https://​doi.​org/​10.​2967/​jnumed.​120.​251447PubMedPubMedCentralCrossRef
157.
Zurück zum Zitat Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong L‑M, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208–1216. https://doi.org/10.1016/S0140-6736(20)30314-7PubMedCrossRef Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong L‑M, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208–1216. https://​doi.​org/​10.​1016/​S0140-6736(20)30314-7PubMedCrossRef
159.
160.
Zurück zum Zitat Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer JCJ, van der Voort van Zijp J, van Vulpen M, Draulans C, van den Bergh L, Isebaert S, van der Heide UA (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39(7):787–796. https://doi.org/10.1200/JCO.20.02873PubMedCrossRef Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer JCJ, van der Voort van Zijp J, van Vulpen M, Draulans C, van den Bergh L, Isebaert S, van der Heide UA (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39(7):787–796. https://​doi.​org/​10.​1200/​JCO.​20.​02873PubMedCrossRef
161.
Zurück zum Zitat Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, Fassbender TF, Bronsert P, Nicolay NH, Gratzke C, Bock M, Ruf J, Benndorf M, Grosu AL (2019) [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard—Implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol 141:214–219. https://doi.org/10.1016/j.radonc.2019.07.005PubMedCrossRef Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, Fassbender TF, Bronsert P, Nicolay NH, Gratzke C, Bock M, Ruf J, Benndorf M, Grosu AL (2019) [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard—Implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol 141:214–219. https://​doi.​org/​10.​1016/​j.​radonc.​2019.​07.​005PubMedCrossRef
162.
Zurück zum Zitat Kostyszyn D, Fechter T, Bartl N, Grosu AL, Gratzke C, Sigle A, Mix M, Ruf J, Fassbender TF, Kiefer S, Bettermann AS, Nicolay NH, Spohn S, Kramer MU, Bronsert P, Guo H, Qiu X, Wang F, Henkenberens C, Werner RA, Baltas D, Meyer PT, Derlin T, Chen M, Zamboglou C (2020) Intraprostatic tumour segmentation on PSMA-PET images in patients with primary prostate cancer with a convolutional neural network. J Nucl Med. https://doi.org/10.2967/jnumed.120.254623PubMedCrossRef Kostyszyn D, Fechter T, Bartl N, Grosu AL, Gratzke C, Sigle A, Mix M, Ruf J, Fassbender TF, Kiefer S, Bettermann AS, Nicolay NH, Spohn S, Kramer MU, Bronsert P, Guo H, Qiu X, Wang F, Henkenberens C, Werner RA, Baltas D, Meyer PT, Derlin T, Chen M, Zamboglou C (2020) Intraprostatic tumour segmentation on PSMA-PET images in patients with primary prostate cancer with a convolutional neural network. J Nucl Med. https://​doi.​org/​10.​2967/​jnumed.​120.​254623PubMedCrossRef
163.
Zurück zum Zitat Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, Kiefer S, Rischke HC, Reichel K, Schmidt-Hegemann N‑S, Ilhan H, Chirindel AF, Nicolas G, Henkenberens C, Derlin T, Bronsert P, Mavroidis P, Chen RC, Meyer PT, Ruf J, Grosu AL (2019) Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol 141:208–213. https://doi.org/10.1016/j.radonc.2019.07.002PubMedCrossRef Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, Kiefer S, Rischke HC, Reichel K, Schmidt-Hegemann N‑S, Ilhan H, Chirindel AF, Nicolas G, Henkenberens C, Derlin T, Bronsert P, Mavroidis P, Chen RC, Meyer PT, Ruf J, Grosu AL (2019) Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol 141:208–213. https://​doi.​org/​10.​1016/​j.​radonc.​2019.​07.​002PubMedCrossRef
164.
165.
Zurück zum Zitat Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, Mix M, Schiller F, Mavroidis P, Meyer PT, Werner M, Grosu AL, Baltas D (2017) Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: a planning study based on histopathology reference. Radiother Oncol 123(3):472–477. https://doi.org/10.1016/j.radonc.2017.04.021PubMedCrossRef Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, Mix M, Schiller F, Mavroidis P, Meyer PT, Werner M, Grosu AL, Baltas D (2017) Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: a planning study based on histopathology reference. Radiother Oncol 123(3):472–477. https://​doi.​org/​10.​1016/​j.​radonc.​2017.​04.​021PubMedCrossRef
167.
Zurück zum Zitat Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T (2019) Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer Prostatic Dis 22(2):344–349. https://doi.org/10.1038/s41391-018-0112-3PubMedCrossRef Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T (2019) Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer Prostatic Dis 22(2):344–349. https://​doi.​org/​10.​1038/​s41391-018-0112-3PubMedCrossRef
170.
Zurück zum Zitat Roy C, Foudi F, Charton J, Jung M, Lang H, Saussine C, Jacqmin D (2013) Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. AJR Am J Roentgenol 200(4):W361–W368. https://doi.org/10.2214/AJR.12.9106PubMedCrossRef Roy C, Foudi F, Charton J, Jung M, Lang H, Saussine C, Jacqmin D (2013) Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. AJR Am J Roentgenol 200(4):W361–W368. https://​doi.​org/​10.​2214/​AJR.​12.​9106PubMedCrossRef
171.
Zurück zum Zitat Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J (2019) 18F‑fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20(9):1286–1294. https://doi.org/10.1016/S1470-2045(19)30415-PubMedPubMedCentralCrossRef Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J (2019) 18F‑fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20(9):1286–1294. https://​doi.​org/​10.​1016/​S1470-2045(19)30415-PubMedPubMedCentralCrossRef
172.
Zurück zum Zitat Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM (2019) Prospective, multisite, international comparison of 〈sup〉18〈/sup〉F-fluoromethylcholine PET/CT, multiparametric MRI, and 〈sup〉68〈/sup〉ga-HBED-CC PSMA-11 PET/CT in men with high-risk features and biochemical failure after radical prostatectomy: clinical performance and patient outcomes. J Nucl Med 60(6):794–800. https://doi.org/10.2967/jnumed.118.220103PubMedPubMedCentralCrossRef Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM (2019) Prospective, multisite, international comparison of 〈sup〉18〈/sup〉F-fluoromethylcholine PET/CT, multiparametric MRI, and 〈sup〉68〈/sup〉ga-HBED-CC PSMA-11 PET/CT in men with high-risk features and biochemical failure after radical prostatectomy: clinical performance and patient outcomes. J Nucl Med 60(6):794–800. https://​doi.​org/​10.​2967/​jnumed.​118.​220103PubMedPubMedCentralCrossRef
173.
Zurück zum Zitat Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015) Prospective comparison of 18F-fluoromethylcholine versus 〈sup〉68〈/sup〉Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56(8):1185–1190. https://doi.org/10.2967/jnumed.115.160382PubMedCrossRef Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015) Prospective comparison of 18F-fluoromethylcholine versus 〈sup〉68〈/sup〉Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56(8):1185–1190. https://​doi.​org/​10.​2967/​jnumed.​115.​160382PubMedCrossRef
174.
Zurück zum Zitat Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V (2020) Interobserver variability, detection rate, and lesion patterns of (68)Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 47(10):2339–2347. https://doi.org/10.1007/s00259-020-04718-wPubMedPubMedCentralCrossRef Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V (2020) Interobserver variability, detection rate, and lesion patterns of (68)Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 47(10):2339–2347. https://​doi.​org/​10.​1007/​s00259-020-04718-wPubMedPubMedCentralCrossRef
175.
Zurück zum Zitat Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—Updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417. https://doi.org/10.1016/j.eururo.2019.01.049PubMedCrossRef Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—Updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417. https://​doi.​org/​10.​1016/​j.​eururo.​2019.​01.​049PubMedCrossRef
176.
Zurück zum Zitat Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber WA, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL (2021) Diagnostic accuracy of 18F‑PSMA-1007 PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence. J Nucl Med 62(2):208–213. https://doi.org/10.2967/jnumed.120.246363PubMedCrossRefPubMedCentral Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber WA, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL (2021) Diagnostic accuracy of 18F‑PSMA-1007 PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence. J Nucl Med 62(2):208–213. https://​doi.​org/​10.​2967/​jnumed.​120.​246363PubMedCrossRefPubMedCentral
177.
Zurück zum Zitat Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K, Beer AJ (2017) Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 44(13):2179–2188. https://doi.org/10.1007/s00259-017-3797-yPubMedCrossRef Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K, Beer AJ (2017) Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 44(13):2179–2188. https://​doi.​org/​10.​1007/​s00259-017-3797-yPubMedCrossRef
178.
Zurück zum Zitat Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A (2020) Whole-body integrated [68Ga]PSMA-11-PET/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET/CT as the standard of reference. Mol Imaging Biol 22(3):788–796. https://doi.org/10.1007/s11307-019-01424-4PubMedCrossRef Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A (2020) Whole-body integrated [68Ga]PSMA-11-PET/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET/CT as the standard of reference. Mol Imaging Biol 22(3):788–796. https://​doi.​org/​10.​1007/​s11307-019-01424-4PubMedCrossRef
180.
Zurück zum Zitat Schiller K, Stöhrer L, Düsberg M, Borm K, Devecka M, Vogel MME, Tauber R, Heck MM, Rauscher I, Eiber M, Gschwend JE, Duma MN, Combs SE (2021) PSMA-PET/CT-based lymph node atlas for prostate cancer patients recurring after primary treatment: clinical implications for salvage radiation therapy. Eur Urol Oncol 4(1):73–83. https://doi.org/10.1016/j.euo.2020.04.004PubMedCrossRef Schiller K, Stöhrer L, Düsberg M, Borm K, Devecka M, Vogel MME, Tauber R, Heck MM, Rauscher I, Eiber M, Gschwend JE, Duma MN, Combs SE (2021) PSMA-PET/CT-based lymph node atlas for prostate cancer patients recurring after primary treatment: clinical implications for salvage radiation therapy. Eur Urol Oncol 4(1):73–83. https://​doi.​org/​10.​1016/​j.​euo.​2020.​04.​004PubMedCrossRef
181.
Zurück zum Zitat Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, Vapiwala N, Calais J, Kishan AU (2021) Use and impact of positron emission tomography/computed tomography prior to salvage radiation therapy in men with biochemical recurrence after radical prostatectomy: a scoping review. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2021.01.007PubMedCrossRef Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, Vapiwala N, Calais J, Kishan AU (2021) Use and impact of positron emission tomography/computed tomography prior to salvage radiation therapy in men with biochemical recurrence after radical prostatectomy: a scoping review. Eur Urol Oncol. https://​doi.​org/​10.​1016/​j.​euo.​2021.​01.​007PubMedCrossRef
182.
Zurück zum Zitat Hurmuz P, Onal C, Ozyigit G, Igdem S, Atalar B, Sayan H, Akgun Z, Kurt M, Ozkok HB, Selek U, Oymak E, Tilki B, Guler OC, Mustafayev TZ, Saricanbaz I, Rzazade R, Akyol F (2020) Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol 196(11):1034–1043. https://doi.org/10.1007/s00066-020-01660-6PubMedCrossRef Hurmuz P, Onal C, Ozyigit G, Igdem S, Atalar B, Sayan H, Akgun Z, Kurt M, Ozkok HB, Selek U, Oymak E, Tilki B, Guler OC, Mustafayev TZ, Saricanbaz I, Rzazade R, Akyol F (2020) Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol 196(11):1034–1043. https://​doi.​org/​10.​1007/​s00066-020-01660-6PubMedCrossRef
183.
Zurück zum Zitat Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, Buck AK, Schirbel A, Bley TA, Wester H‑J, Vergho D, Becker A (2016) Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res 6(1):78. https://doi.org/10.1186/s13550-016-0233-4PubMedPubMedCentralCrossRef Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, Buck AK, Schirbel A, Bley TA, Wester H‑J, Vergho D, Becker A (2016) Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res 6(1):78. https://​doi.​org/​10.​1186/​s13550-016-0233-4PubMedPubMedCentralCrossRef
184.
Zurück zum Zitat Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE (2017) 68Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate 77(8):920–927. https://doi.org/10.1002/pros.23347PubMedCrossRef Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE (2017) 68Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate 77(8):920–927. https://​doi.​org/​10.​1002/​pros.​23347PubMedCrossRef
185.
188.
Zurück zum Zitat Scott AM, Gunawardana DH, Wong J, Kirkwood I, Hicks RJ, Ho Shon I, Ramshaw JE, Robins P (2009) Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 36(3):347–353. https://doi.org/10.1007/s00259-008-0958-zPubMedCrossRef Scott AM, Gunawardana DH, Wong J, Kirkwood I, Hicks RJ, Ho Shon I, Ramshaw JE, Robins P (2009) Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 36(3):347–353. https://​doi.​org/​10.​1007/​s00259-008-0958-zPubMedCrossRef
190.
Zurück zum Zitat Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh C‑O, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG (2019) Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood 133(3):237–245. https://doi.org/10.1182/blood-2018-04-843540PubMedCrossRef Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh C‑O, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG (2019) Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood 133(3):237–245. https://​doi.​org/​10.​1182/​blood-2018-04-843540PubMedCrossRef
191.
Zurück zum Zitat MacManus M, Fisher R, Roos D, O’Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour JF (2018) Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol 36(29):2918–2925. https://doi.org/10.1200/jco.2018.77.9892PubMedCrossRef MacManus M, Fisher R, Roos D, O’Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour JF (2018) Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol 36(29):2918–2925. https://​doi.​org/​10.​1200/​jco.​2018.​77.​9892PubMedCrossRef
193.
194.
Zurück zum Zitat Terezakis SA, Schoder H, Kowalski A, McCann P, Schmidtlein C, Gonen M, Kirov A, Lovie S, Yahalom J (2010) A prospective study of 18FDG-PET with CT scan co-registration for radiation treatment planning of lymphoma and hematologic malignancies. Int J Radiat Oncol Biol Phys 78(3):550. https://doi.org/10.1016/j.ijrobp.2010.07.1284CrossRef Terezakis SA, Schoder H, Kowalski A, McCann P, Schmidtlein C, Gonen M, Kirov A, Lovie S, Yahalom J (2010) A prospective study of 18FDG-PET with CT scan co-registration for radiation treatment planning of lymphoma and hematologic malignancies. Int J Radiat Oncol Biol Phys 78(3):550. https://​doi.​org/​10.​1016/​j.​ijrobp.​2010.​07.​1284CrossRef
199.
Zurück zum Zitat Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma—Target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89(1):49–58. https://doi.org/10.1016/j.ijrobp.2014.01.006PubMedCrossRef Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma—Target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89(1):49–58. https://​doi.​org/​10.​1016/​j.​ijrobp.​2014.​01.​006PubMedCrossRef
200.
Zurück zum Zitat Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862. https://doi.org/10.1016/j.ijrobp.2013.05.005PubMedCrossRef Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862. https://​doi.​org/​10.​1016/​j.​ijrobp.​2013.​05.​005PubMedCrossRef
203.
Zurück zum Zitat Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32(27):3048–3058. https://doi.org/10.1200/JCO.2013.53.5229PubMedPubMedCentralCrossRef Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32(27):3048–3058. https://​doi.​org/​10.​1200/​JCO.​2013.​53.​5229PubMedPubMedCentralCrossRef
204.
Zurück zum Zitat Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d’Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O’Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S (2016) Adapted Treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374(25):2419–2429. https://doi.org/10.1056/NEJMoa1510093PubMedPubMedCentralCrossRef Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d’Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O’Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S (2016) Adapted Treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374(25):2419–2429. https://​doi.​org/​10.​1056/​NEJMoa1510093PubMedPubMedCentralCrossRef
205.
Zurück zum Zitat Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O’Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607. https://doi.org/10.1056/NEJMoa1408648PubMedCrossRef Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O’Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607. https://​doi.​org/​10.​1056/​NEJMoa1408648PubMedCrossRef
206.
Zurück zum Zitat André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794. https://doi.org/10.1200/jco.2016.68.6394PubMedCrossRef André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794. https://​doi.​org/​10.​1200/​jco.​2016.​68.​6394PubMedCrossRef
207.
Zurück zum Zitat Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol 37(31):2835–2845. https://doi.org/10.1200/jco.19.00964PubMedCrossRef Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A (2019) Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol 37(31):2835–2845. https://​doi.​org/​10.​1200/​jco.​19.​00964PubMedCrossRef
208.
Zurück zum Zitat Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194. https://doi.org/10.1200/jco.2013.51.9298PubMedCrossRef Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194. https://​doi.​org/​10.​1200/​jco.​2013.​51.​9298PubMedCrossRef
209.
Zurück zum Zitat van den Bosch S, Doornaert PAH, Dijkema T, Zwijnenburg EM, Verhoef LCG, Hoeben BAW, Kasperts N, Smid EJ, Terhaard CHJ, Kaanders JHAM (2020) FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival. Radiother Oncol 142:107–114. https://doi.org/10.1016/j.radonc.2019.07.025PubMedCrossRef van den Bosch S, Doornaert PAH, Dijkema T, Zwijnenburg EM, Verhoef LCG, Hoeben BAW, Kasperts N, Smid EJ, Terhaard CHJ, Kaanders JHAM (2020) FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival. Radiother Oncol 142:107–114. https://​doi.​org/​10.​1016/​j.​radonc.​2019.​07.​025PubMedCrossRef
210.
Zurück zum Zitat Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, Thorwarth D, Fidarova E, Paez D, Chiti A, Hanna GG (2015) PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol 116(1):27–34. https://doi.org/10.1016/j.radonc.2015.03.014PubMedCrossRef Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, Thorwarth D, Fidarova E, Paez D, Chiti A, Hanna GG (2015) PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol 116(1):27–34. https://​doi.​org/​10.​1016/​j.​radonc.​2015.​03.​014PubMedCrossRef
213.
Zurück zum Zitat Zwirner K, Thorwarth D, Winter RM, Welz S, Weiss J, Schwenzer NF, Schmidt H, la Fougère C, Nikolaou K, Zips D, Gatidis S (2018) Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup. Strahlenther Onkol 194(8):719–726. https://doi.org/10.1007/s00066-018-1292-4PubMedCrossRef Zwirner K, Thorwarth D, Winter RM, Welz S, Weiss J, Schwenzer NF, Schmidt H, la Fougère C, Nikolaou K, Zips D, Gatidis S (2018) Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup. Strahlenther Onkol 194(8):719–726. https://​doi.​org/​10.​1007/​s00066-018-1292-4PubMedCrossRef
215.
Zurück zum Zitat Mac Manus MP, Everitt S, Bayne M, Ball D, Plumridge N, Binns D, Herschtal A, Cruickshank D, Bressel M, Hicks RJ (2013) The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. Radiother Oncol 106(3):292–298. https://doi.org/10.1016/j.radonc.2012.12.018PubMedCrossRef Mac Manus MP, Everitt S, Bayne M, Ball D, Plumridge N, Binns D, Herschtal A, Cruickshank D, Bressel M, Hicks RJ (2013) The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. Radiother Oncol 106(3):292–298. https://​doi.​org/​10.​1016/​j.​radonc.​2012.​12.​018PubMedCrossRef
217.
Zurück zum Zitat Thorwarth D, Beyer T, Boellaard R, De Ruysscher D, Grgic A, Lee JA, Pietrzyk U, Sattler B, Schaefer A, van Elmpt W, Vogel W, Oyen WJG, Nestle U (2012) Integration of FDG-PET/CT into external beam radiation therapy planning. Nuklearmedizin 51(04):140–153PubMedCrossRef Thorwarth D, Beyer T, Boellaard R, De Ruysscher D, Grgic A, Lee JA, Pietrzyk U, Sattler B, Schaefer A, van Elmpt W, Vogel W, Oyen WJG, Nestle U (2012) Integration of FDG-PET/CT into external beam radiation therapy planning. Nuklearmedizin 51(04):140–153PubMedCrossRef
219.
Zurück zum Zitat Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328–354. https://doi.org/10.1007/s00259-014-2961-xPubMedCrossRef Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328–354. https://​doi.​org/​10.​1007/​s00259-014-2961-xPubMedCrossRef
220.
Zurück zum Zitat Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, Comans EF, Pruim J (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35(12):2320–2333. https://doi.org/10.1007/s00259-008-0874-2PubMedCrossRef Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, Comans EF, Pruim J (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35(12):2320–2333. https://​doi.​org/​10.​1007/​s00259-008-0874-2PubMedCrossRef
223.
Zurück zum Zitat Shepherd T, Teras M, Beichel RR, Boellaard R, Bruynooghe M, Dicken V, Gooding MJ, Julyan PJ, Lee JA, Lefevre S, Mix M, Naranjo V, Wu X, Zaidi H, Zeng Z, Minn H (2012) Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. IEEE Trans Med Imaging 31(11):2006–2024. https://doi.org/10.1109/TMI.2012.2202322PubMedPubMedCentralCrossRef Shepherd T, Teras M, Beichel RR, Boellaard R, Bruynooghe M, Dicken V, Gooding MJ, Julyan PJ, Lee JA, Lefevre S, Mix M, Naranjo V, Wu X, Zaidi H, Zeng Z, Minn H (2012) Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. IEEE Trans Med Imaging 31(11):2006–2024. https://​doi.​org/​10.​1109/​TMI.​2012.​2202322PubMedPubMedCentralCrossRef
227.
Zurück zum Zitat Feng Q, Liang J, Wang L, Niu J, Ge X, Pang P, Ding Z (2020) Radiomics analysis and correlation with metabolic parameters in nasopharyngeal carcinoma based on PET/MR imaging. Front Oncol 10:1619PubMedPubMedCentralCrossRef Feng Q, Liang J, Wang L, Niu J, Ge X, Pang P, Ding Z (2020) Radiomics analysis and correlation with metabolic parameters in nasopharyngeal carcinoma based on PET/MR imaging. Front Oncol 10:1619PubMedPubMedCentralCrossRef
234.
Zurück zum Zitat Carré A, Klausner G, Edjlali M, Lerousseau M, Briend-Diop J, Sun R, Ammari S, Reuzé S, Alvarez Andres E, Estienne T, Niyoteka S, Battistella E, Vakalopoulou M, Dhermain F, Paragios N, Deutsch E, Oppenheim C, Pallud J, Robert C (2020) Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics. Sci Rep 10(1):12340. https://doi.org/10.1038/s41598-020-69298-zPubMedPubMedCentralCrossRef Carré A, Klausner G, Edjlali M, Lerousseau M, Briend-Diop J, Sun R, Ammari S, Reuzé S, Alvarez Andres E, Estienne T, Niyoteka S, Battistella E, Vakalopoulou M, Dhermain F, Paragios N, Deutsch E, Oppenheim C, Pallud J, Robert C (2020) Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics. Sci Rep 10(1):12340. https://​doi.​org/​10.​1038/​s41598-020-69298-zPubMedPubMedCentralCrossRef
235.
Zurück zum Zitat Depeursinge A, Andrearczyk V, Whybra P, van Griethuysen J, Müller H, Schaer R, Vallières M, Zwanenburg A (2020) Standardised convolutional filtering for radiomics (arXiv:2006.05470 [cs.CV]) Depeursinge A, Andrearczyk V, Whybra P, van Griethuysen J, Müller H, Schaer R, Vallières M, Zwanenburg A (2020) Standardised convolutional filtering for radiomics (arXiv:2006.05470 [cs.CV])
237.
Zurück zum Zitat Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit M‑C, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Götz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegård A, Maier-Hein KH, Morin O, Müller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, Löck S (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2):328–338. https://doi.org/10.1148/radiol.2020191145PubMedCrossRef Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit M‑C, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Götz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegård A, Maier-Hein KH, Morin O, Müller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, Löck S (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2):328–338. https://​doi.​org/​10.​1148/​radiol.​2020191145PubMedCrossRef
241.
Zurück zum Zitat Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, Yin Y, Fu Z, Mu D, Zhang B, He W, Huo Z, Liu X, Kong L, Zhao S, Sun X (2010) Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 76(4):1235–1241. https://doi.org/10.1016/j.ijrobp.2009.07.1681PubMedCrossRef Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, Yin Y, Fu Z, Mu D, Zhang B, He W, Huo Z, Liu X, Kong L, Zhao S, Sun X (2010) Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 76(4):1235–1241. https://​doi.​org/​10.​1016/​j.​ijrobp.​2009.​07.​1681PubMedCrossRef
242.
Zurück zum Zitat Liu J, Li C, Hu M, Lu J, Shi X, Xing L, Sun X, Fu Z, Yu J, Meng X (2015) Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study. Medicine 94(17):e678–e678. https://doi.org/10.1097/MD.0000000000000678PubMedPubMedCentralCrossRef Liu J, Li C, Hu M, Lu J, Shi X, Xing L, Sun X, Fu Z, Yu J, Meng X (2015) Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study. Medicine 94(17):e678–e678. https://​doi.​org/​10.​1097/​MD.​0000000000000678​PubMedPubMedCentralCrossRef
246.
Zurück zum Zitat Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, Staudinger F, Tonndorf-Martini E, Regnery S, Rieken S, El Shafie R, Röhrich M, Flechsig P, Kluge A, Altmann A, Debus J, Haberkorn U, Kratochwil C (2021) FAPI-74 PET/CT using either 18F‑AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med 62(2):201. https://doi.org/10.2967/jnumed.120.245084PubMedCrossRefPubMedCentral Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, Staudinger F, Tonndorf-Martini E, Regnery S, Rieken S, El Shafie R, Röhrich M, Flechsig P, Kluge A, Altmann A, Debus J, Haberkorn U, Kratochwil C (2021) FAPI-74 PET/CT using either 18F‑AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med 62(2):201. https://​doi.​org/​10.​2967/​jnumed.​120.​245084PubMedCrossRefPubMedCentral
248.
Zurück zum Zitat Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE (2018) (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24(12):1852–1858. https://doi.org/10.1038/s41591-018-0255-8PubMedCrossRef Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE (2018) (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24(12):1852–1858. https://​doi.​org/​10.​1038/​s41591-018-0255-8PubMedCrossRef
249.
Zurück zum Zitat Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY (2019) EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer. Cancer Discov 9(2):199–209. https://doi.org/10.1158/2159-8290.Cd-18-0598PubMedCrossRef Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY (2019) EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer. Cancer Discov 9(2):199–209. https://​doi.​org/​10.​1158/​2159-8290.​Cd-18-0598PubMedCrossRef
250.
Zurück zum Zitat Lohrmann C, O’Reilly EM, O’Donoghue JA, Pandit-Taskar N, Carrasquillo JA, Lyashchenko SK, Ruan S, Teng R, Scholz W, Maffuid PW, Lewis JS, Weber WA (2019) Retooling a blood-based Biomarker: phase I assessment of the high-affinity CA19‑9 antibody HuMab-5B1 for Immuno-PET imaging of pancreatic cancer. Clin Cancer Res 25(23):7014–7023. https://doi.org/10.1158/1078-0432.Ccr-18-3667PubMedPubMedCentralCrossRef Lohrmann C, O’Reilly EM, O’Donoghue JA, Pandit-Taskar N, Carrasquillo JA, Lyashchenko SK, Ruan S, Teng R, Scholz W, Maffuid PW, Lewis JS, Weber WA (2019) Retooling a blood-based Biomarker: phase I assessment of the high-affinity CA19‑9 antibody HuMab-5B1 for Immuno-PET imaging of pancreatic cancer. Clin Cancer Res 25(23):7014–7023. https://​doi.​org/​10.​1158/​1078-0432.​Ccr-18-3667PubMedPubMedCentralCrossRef
252.
Zurück zum Zitat Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, Reischl G, Mauz P‑S, Paulsen F, Alber M, Belka C, Zips D, Thorwarth D (2017) Prognostic value of dynamic hypoxia PET in head and neck cancer: results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol 124(3):526–532. https://doi.org/10.1016/j.radonc.2017.04.004PubMedCrossRef Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, Reischl G, Mauz P‑S, Paulsen F, Alber M, Belka C, Zips D, Thorwarth D (2017) Prognostic value of dynamic hypoxia PET in head and neck cancer: results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol 124(3):526–532. https://​doi.​org/​10.​1016/​j.​radonc.​2017.​04.​004PubMedCrossRef
253.
Zurück zum Zitat Zschaeck S, Löck S, Hofheinz F, Zips D, Saksø Mortensen L, Zöphel K, Troost EGC, Boeke S, Saksø M, Mönnich D, Seidlitz A, Johansen J, Skripcak T, Gregoire V, Overgaard J, Baumann M, Krause M (2020) Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiother Oncol 149:189–196. https://doi.org/10.1016/j.radonc.2020.05.022PubMedCrossRef Zschaeck S, Löck S, Hofheinz F, Zips D, Saksø Mortensen L, Zöphel K, Troost EGC, Boeke S, Saksø M, Mönnich D, Seidlitz A, Johansen J, Skripcak T, Gregoire V, Overgaard J, Baumann M, Krause M (2020) Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiother Oncol 149:189–196. https://​doi.​org/​10.​1016/​j.​radonc.​2020.​05.​022PubMedCrossRef
254.
Zurück zum Zitat Thorwarth D, Welz S, Monnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougere C, Reischl G, Mauz PS, Paulsen F, Alber M, Belka C, Zips D (2019) Prospective evaluation of a tumor control probability model based on dynamic F‑18-FMISO PET for head and neck cancer radiotherapy. J Nucl Med 60(12):1698–1704. https://doi.org/10.2967/jnumed.119.227744PubMedPubMedCentralCrossRef Thorwarth D, Welz S, Monnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougere C, Reischl G, Mauz PS, Paulsen F, Alber M, Belka C, Zips D (2019) Prospective evaluation of a tumor control probability model based on dynamic F‑18-FMISO PET for head and neck cancer radiotherapy. J Nucl Med 60(12):1698–1704. https://​doi.​org/​10.​2967/​jnumed.​119.​227744PubMedPubMedCentralCrossRef
256.
Zurück zum Zitat Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL (2018) Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. Radiat Oncol 13(1):159. https://doi.org/10.1186/s13014-018-1103-1PubMedPubMedCentralCrossRef Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL (2018) Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. Radiat Oncol 13(1):159. https://​doi.​org/​10.​1186/​s13014-018-1103-1PubMedPubMedCentralCrossRef
257.
Zurück zum Zitat Lee N, Schoder H, Beattie B, Lanning R, Riaz N, McBride S, Katabi N, Li D, Yarusi B, Chan S, Mitrani L, Zhang Z, Pfister DG, Sherman E, Baxi S, Boyle J, Morris LGT, Ganly I, Wong R, Humm J (2016) Strategy of using Intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 96(1):9–17. https://doi.org/10.1016/j.ijrobp.2016.04.027PubMedPubMedCentralCrossRef Lee N, Schoder H, Beattie B, Lanning R, Riaz N, McBride S, Katabi N, Li D, Yarusi B, Chan S, Mitrani L, Zhang Z, Pfister DG, Sherman E, Baxi S, Boyle J, Morris LGT, Ganly I, Wong R, Humm J (2016) Strategy of using Intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 96(1):9–17. https://​doi.​org/​10.​1016/​j.​ijrobp.​2016.​04.​027PubMedPubMedCentralCrossRef
259.
Zurück zum Zitat van Diessen J, De Ruysscher D, Sonke J‑J, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J (2019) The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiother Oncol 131:166–173. https://doi.org/10.1016/j.radonc.2018.09.019PubMedCrossRef van Diessen J, De Ruysscher D, Sonke J‑J, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J (2019) The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiother Oncol 131:166–173. https://​doi.​org/​10.​1016/​j.​radonc.​2018.​09.​019PubMedCrossRef
Metadaten
Titel
Value of PET imaging for radiation therapy
verfasst von
Constantin Lapa
Ursula Nestle
Nathalie L. Albert
Christian Baues
Ambros Beer
Andreas Buck
Volker Budach
Rebecca Bütof
Stephanie E. Combs
Thorsten Derlin
Matthias Eiber
Wolfgang P. Fendler
Christian Furth
Cihan Gani
Eleni Gkika
Anca-L. Grosu
Christoph Henkenberens
Harun Ilhan
Steffen Löck
Simone Marnitz-Schulze
Matthias Miederer
Michael Mix
Nils H. Nicolay
Maximilian Niyazi
Christoph Pöttgen
Claus M. Rödel
Imke Schatka
Sarah M. Schwarzenboeck
Andrei S. Todica
Wolfgang Weber
Simone Wegen
Thomas Wiegel
Constantinos Zamboglou
Daniel Zips
Klaus Zöphel
Sebastian Zschaeck
Daniela Thorwarth
Esther G. C. Troost, MD PhD
Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN
Publikationsdatum
14.07.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 9/2021
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-021-01812-2

Weitere Artikel der Ausgabe 9/2021

Strahlentherapie und Onkologie 9/2021 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.